. Author manuscript; available in PMC: 2014 Jul 21.

Published in final edited form as: Eur J Clin Nutr. 2007 May 30;62(8):1031–1037. doi: 10.1038/sj.ejcn.1602793

Table 1.

Baseline demographic and laboratory characteristics of all study subjects (n=16)

	n (%) or median (range)
Age (years)	49 (39–63)
Sex (male)	11 (69%)
Race
White	8 (50%)
African-Americans	7 (44%)
Asian	1 (6%)
Duration of HIV (months)	105 (33–235)
Duration of NRTI therapy (months)	82 (33–216)
Duration of stavudine therapy (months)	48 (9–120)
ALT (U/l)	47 (30–108)
Creatinine kinase (U/l)	126 (33–369)
Hemoglobin (g/dl)	(12.9–18.6)
CD4+ cell count (cells/mm³)	556 (222–1636)
HIV-1 RNA <50 copies/ml	13 (81%)
Antiretrovirals used at study entry
Stavudine	16 (100%)
Lamivudine	10 (62.5%)
Abacavir	2 (12.5%)
Tenofovir	2 (12.5%)
PI	8 (50%)
NNRTI	9 (56%)
Enfuvirtide	1 (6%)

Abbreviations: ALT, alanine aminotransferase; HIV-1, human immunodeficiency- 1; NNRTI, non-nucleoside reverse transcriptase inhibitor, NRTI, nucleoside reverse transcriptase inhibitor.